Drug Profile
Batifiban - by Bio-Thera Solutions
Alternative Names: BAT 2094; CorrectinLatest Information Update: 27 Jun 2022
Price :
$50
*
At a glance
- Originator Bio-Thera Solutions
- Class Antithrombotics; Cyclic peptides; Sulfhydryl compounds
- Mechanism of Action GPIIb-IIIa antagonists; Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Acute coronary syndromes
Most Recent Events
- 27 Jun 2022 Preregistration for Acute coronary syndromes in China (IV), before June 2022 (Bio-Thera Solutions pipeline, June 2022)
- 11 Oct 2021 No development reported - Phase-III for Acute coronary syndromes in China (IV)
- 22 Oct 2018 Chemical structure information added